Lynn Symonds1, Hannah Linden2, Vijayakrishna Gadi2, Larissa Korde3, Eve Rodler4, Julie Gralow2, Mary Redman5, Kelsey Baker5, Quan Vicky Wu5, Isaac Jenkins5, Brenda Kurland6, Mitchell Garrison7, Julie Smith7, Jeanne Anderson8, Carol Van Haelst1, Jennifer Specht9. 1. Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. 2. Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. National Cancer Institute, Rockville, MD. 4. Division of Oncology and Hematology, Department of Internal Medicine, UC Davis Health, Sacramento, CA. 5. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 6. University of Pittsburgh, Pittsburgh, PA. 7. Confluence Health at Wenatchee Valley, Wenatchee, WA. 8. Katmai Oncology Group, Anchorage, AK. 9. Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: jspecht@uw.edu.
Abstract
INTRODUCTION: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC. During induction, the patients received nab-paclitaxel 100 mg/m2 intravenously (days 1, 8, and 15) and bevacizumab 10 mg/kg intravenously (days 1 and 15) every 28 days for 6 cycles. Patients free of progression at 24 weeks received maintenance therapy with bevacizumab 10 mg/kg intravenously every 2 weeks and oral erlotinib 150 mg/d until disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were best overall response, overall survival (OS), and adverse events. We explored the measurement of circulating tumor cells as a prognostic marker. RESULTS: A total of 55 evaluable patients were enrolled. The median PFS and OS for the cohort was 9.1 months (95% confidence interval, 7.2-11.1) and 18.1 months (95% confidence interval, 15.6-21.7), respectively. Of the 53 patients with measurable disease, 39 (74%) had experienced a partial response and 10 (19%) had stable disease using the Response Evaluation Criteria In Solid Tumors. The most common toxicities were uncomplicated neutropenia, fatigue, and neuropathy. Decreased circulating tumor cells from baseline to the first assessment correlated with longer PFS and OS. CONCLUSION: Nab-paclitaxel and bevacizumab, followed by maintenance targeted therapy with bevacizumab and erlotinib, resulted in PFS similar to that of other trials. Most patients experienced a partial response (74%). Most patients received maintenance therapy (55%), providing a break from cytotoxic chemotherapy.
INTRODUCTION: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC. During induction, the patients received nab-paclitaxel 100 mg/m2 intravenously (days 1, 8, and 15) and bevacizumab 10 mg/kg intravenously (days 1 and 15) every 28 days for 6 cycles. Patients free of progression at 24 weeks received maintenance therapy with bevacizumab 10 mg/kg intravenously every 2 weeks and oral erlotinib 150 mg/d until disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were best overall response, overall survival (OS), and adverse events. We explored the measurement of circulating tumor cells as a prognostic marker. RESULTS: A total of 55 evaluable patients were enrolled. The median PFS and OS for the cohort was 9.1 months (95% confidence interval, 7.2-11.1) and 18.1 months (95% confidence interval, 15.6-21.7), respectively. Of the 53 patients with measurable disease, 39 (74%) had experienced a partial response and 10 (19%) had stable disease using the Response Evaluation Criteria In Solid Tumors. The most common toxicities were uncomplicated neutropenia, fatigue, and neuropathy. Decreased circulating tumor cells from baseline to the first assessment correlated with longer PFS and OS. CONCLUSION:Nab-paclitaxel and bevacizumab, followed by maintenance targeted therapy with bevacizumab and erlotinib, resulted in PFS similar to that of other trials. Most patients experienced a partial response (74%). Most patients received maintenance therapy (55%), providing a break from cytotoxic chemotherapy.
Authors: Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544
Authors: Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: F-C Bidard; C Mathiot; A Degeorges; M-C Etienne-Grimaldi; R Delva; X Pivot; C Veyret; L Bergougnoux; P de Cremoux; G Milano; J-Y Pierga Journal: Ann Oncol Date: 2010-03-16 Impact factor: 32.976
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Maura N Dickler; Hope S Rugo; Carey A Eberle; Edi Brogi; James F Caravelli; Katherine S Panageas; Jeff Boyd; Benjamin Yeh; Diana E Lake; Chau T Dang; Teresa A Gilewski; Jacqueline F Bromberg; Andrew D Seidman; Gabriella M D'Andrea; Mark M Moasser; Michele Melisko; John W Park; Janet Dancey; Larry Norton; Clifford A Hudis Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe Journal: Cell Date: 2012-05-11 Impact factor: 41.582
Authors: Francisco Rodríguez; Pablo Caruana; Noa De la Fuente; Pía Español; María Gámez; Josep Balart; Elisa Llurba; Ramón Rovira; Raúl Ruiz; Cristina Martín-Lorente; José Luis Corchero; María Virtudes Céspedes Journal: Biomolecules Date: 2022-06-04